Engineering a multi-target therapy nanoplatform against tumor growth and metastasis via a novel NSAID-Pt(IV) prodrug

Di Zhang1, Jing Nie1, Dongbo Wang1

  • 1Department of Pharmacy, Shandong Second Provincial General Hospital, 4 West Duanxing Road, Jinan, Shandong Province 250022, China. wujiyongsdcn@gmail.com.

Chemical Communications (Cambridge, England)
|March 1, 2022
PubMed

Insights

This study introduces a novel nanoplatform combining cisplatin (CDDP) and bendazac (Ben) for multi-target cancer therapy. This innovative approach effectively combats tumor growth and metastasis.

Area of Science:

  • Oncology
  • Nanomedicine
  • Drug Delivery

Background:

  • Tumor growth and metastasis are complex processes driven by multiple factors.
  • Effective cancer treatment requires multi-target strategies to address this complexity.

Purpose of the Study:

  • To develop a novel nanoplatform for combating tumor growth and metastasis.
  • To combine cisplatin (CDDP) and bendazac (Ben) into a single, targeted therapeutic agent.

Main Methods:

  • Design and synthesis of a novel NSAID-Pt(IV) nanoplatform.
  • Evaluation of the nanoplatform's efficacy against tumor growth and metastasis.

Main Results:

  • The developed NSAID-Pt(IV) nanoplatform demonstrated effectiveness in combating tumor growth.
  • The nanoplatform showed significant potential in inhibiting metastasis.

Conclusions:

  • A novel NSAID-Pt(IV) nanoplatform combining CDDP and Ben offers a promising multi-target strategy.
  • This nanoplatform is an effective weapon against tumor growth and metastasis.